← Leaderboards
Andrew Peter Mallon
Calista Therapeutics, Inc.
$3,280,261
Attributed
$3,404,260
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2013–22$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,404,260 · 4
By mechanism
UG3$2,831,838 · 1
R43$472,991 · 2
UH3$99,431 · 1
Top collaborators
- Rajiv Ravindra Mohan1 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchPharmaceutical PreparationsPreclinical StudyDoseBaseAwardSuccessSafetyTimelineFormulationFutureEnsureInnovationToxic EffectMeetingsInvestmentsLeadGrantHistopathologyLifeCostEffective TherapyCommercializationComparative
Grant awards (4)
Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder.$99,431
UH3 · FY2022 · DA · contact PI
Development of a selective PI3K-Akt-activating neurotrophic small molecule drug, MT-002, for the healing of corneal wounds in Neurotrophic Keratitis.$247,998
R43 · FY2021 · EY · contact PI
Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder.$2,831,838
UG3 · FY2020 · DA · contact PI
Therapeutic correction of deltaF508-CFTR cystic fibrosis by a novel PDZ12 drug.$224,993
R43 · FY2013 · HL · contact PI